By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A BG Medicine official said that the company has not pulled its initial public offering, despite being unable to price it thus far.

In an e-mail to GenomeWeb Daily News, Stacie Rader, senior vice president of executive operations and human resources for the firm, denied a Dow Jones Newswire article, which stated that the Waltham, Mass., biomarker development firm had abandoned its IPO because it had been unable to price it during the week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.